BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17536794)

  • 1. Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
    Singleton DH; Boyd H; Steidl-Nichols JV; Deacon M; Groot MJ; Price D; Nettleton DO; Wallace NK; Troutman MD; Williams C; Boyd JG
    J Med Chem; 2007 Jun; 50(13):2931-41. PubMed ID: 17536794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring chemical substructures essential for HERG k(+) channel blockade by synthesis and biological evaluation of dofetilide analogues.
    ; Guo D; Klaasse E; de Vries H; Brussee J; Nalos L; Rook MB; Vos MA; van der Heyden MA; Ijzerman AP
    ChemMedChem; 2009 Oct; 4(10):1722-32. PubMed ID: 19725081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
    Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
    J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide.
    Carvalho JF; Louvel J; Doornbos ML; Klaasse E; Yu Z; Brussee J; IJzerman AP
    J Med Chem; 2013 Apr; 56(7):2828-40. PubMed ID: 23473309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
    Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
    J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue.
    Varkevisser R; Houtman MJ; Linder T; de Git KC; Beekman HD; Tidwell RR; Ijzerman AP; Stary-Weinzinger A; Vos MA; van der Heyden MA
    Br J Pharmacol; 2013 Jul; 169(6):1322-34. PubMed ID: 23586323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs.
    Yu Z; Klaasse E; Heitman LH; Ijzerman AP
    Toxicol Appl Pharmacol; 2014 Jan; 274(1):78-86. PubMed ID: 24200993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. F463L increases the potential of dofetilide on human ether-a-go-go-related gene (hERG) channels.
    Cheng G; Wu J; Han W; Sun C
    Microsc Res Tech; 2018 Jun; 81(6):663-668. PubMed ID: 29573040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
    Limberis JT; Su Z; Cox BF; Gintant GA; Martin RL
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1059-65. PubMed ID: 17042915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
    Dong DL; Li Z; Wang HZ; Du ZM; Song WH; Yang BF
    Basic Clin Pharmacol Toxicol; 2004 May; 94(5):209-12. PubMed ID: 15125690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High affinity open channel block by dofetilide of HERG expressed in a human cell line.
    Snyders DJ; Chaudhary A
    Mol Pharmacol; 1996 Jun; 49(6):949-55. PubMed ID: 8649354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis.
    DU CY; El Harchi A; Zhang YH; Orchard CH; Hancox JC
    J Cardiovasc Electrophysiol; 2011 Oct; 22(10):1163-70. PubMed ID: 21489024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel.
    Murphy SM; Palmer M; Poole MF; Padegimas L; Hunady K; Danzig J; Gill S; Gill R; Ting A; Sherf B; Brunden K; Stricker-Krongrad A
    J Pharmacol Toxicol Methods; 2006; 54(1):42-55. PubMed ID: 16326118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
    Schmidtke P; Ciantar M; Theret I; Ducrot P
    J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
    Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
    Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions at human ether-à-go-go-related gene channels.
    Friemel A; Zünkler BJ
    Toxicol Sci; 2010 Apr; 114(2):346-55. PubMed ID: 20071423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
    Potet F; Lorinc AN; Chaigne S; Hopkins CR; Venkataraman R; Stepanovic SZ; Lewis LM; Days E; Sidorov VY; Engers DW; Zou B; Afshartous D; George AL; Campbell CM; Balser JR; Li M; Baudenbacher FJ; Lindsley CW; Weaver CD; Kupershmidt S
    J Biol Chem; 2012 Nov; 287(47):39613-25. PubMed ID: 23033485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of the predictor HERG fluorescence polarization assay using a membrane protein enrichment approach.
    Piper DR; Duff SR; Eliason HC; Frazee WJ; Frey EA; Fuerstenau-Sharp M; Jachec C; Marks BD; Pollok BA; Shekhani MS; Thompson DV; Whitney P; Vogel KW; Hess SD
    Assay Drug Dev Technol; 2008 Apr; 6(2):213-23. PubMed ID: 18471075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of negative allosteric modulators of the Kv11.1(hERG) channel.
    Yu Z; van Veldhoven JP; 't Hart IM; Kopf AH; Heitman LH; IJzerman AP
    Eur J Med Chem; 2015 Dec; 106():50-9. PubMed ID: 26519929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.
    Rampe D; Murawsky MK; Grau J; Lewis EW
    J Pharmacol Exp Ther; 1998 Aug; 286(2):788-93. PubMed ID: 9694935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.